Latest Healthcare Sector News

FOS Capital's subsidiary has landed a $1 million contract for lighting at Monash Medical Clinic, boosting its order book to $10 million and reinforcing its healthcare sector presence.

Optiscan Imaging has begun commercial sales of its InSpecta™ microscopic imaging device in the US veterinary sector following FDA clearance, marking its first clinical device launch and a strategic expansion into a $15.87 billion market.

ReNerve Limited has secured regulatory approval to market its flagship NervAlign Nerve Cuff in Indonesia, marking a major step in its Asia-Pacific expansion and unlocking access to one of the region’s largest nerve repair markets.

Cann Group has boosted its private credit loan facility by $2 million to facilitate the early redemption of convertible notes, maintaining its debt restructuring momentum.

Algorae Pharmaceuticals has been appointed as a supplier under a NSW Health public hospital supply contract, marking a strategic milestone despite uncertain immediate revenue impact.

Algorae Pharmaceuticals has clinched a multi-year public hospital supply contract with NSW Health, marking a significant commercial milestone. The rollout is set to begin in the fourth quarter of 2026, underpinning the company's growth ambitions in the Australian healthcare market.

Visionflex Group has landed a $0.8 million contract to supply clinical hardware for NSW Health’s statewide Remote Patient Monitoring Digital Uplift, reinforcing its role in virtual healthcare expansion.

Imagion Biosystems has raised $3.75 million to fund the start of its Phase 1b/2 clinical trial for the MagSense HER2 imaging agent in the US, following FDA clearance. The capital raising involves a two-tranche share placement with free attaching options, led by CPS Capital.

Pro Medicus has inked a binding Heads of Agreement with Echo IQ to finance and resell AI algorithms targeting cardiovascular conditions, aiming to integrate these into its Visage 7 Cardiology platform.

SDI Limited shareholders voted overwhelmingly in favour of a $1.40 per share acquisition scheme by InnoXvest Dental, setting the stage for court approval and delisting.

Arena REIT has declared its June 2026 quarterly distribution at 4.8125 cents per security, consistent with its full-year guidance, and is offering a Dividend Reinvestment Plan with a 1.5% discount to encourage reinvestment.

Vita Life Sciences projects a slight increase in H1 2026 sales and stable pre-tax profits, supported by strong markets in Australia and Malaysia/Singapore but offset by regulatory headwinds in China.